Viral infections in inflammatory bowel disease: Tips and tricks for correct management
- PMID: 34366605
- PMCID: PMC8316900
- DOI: 10.3748/wjg.v27.i27.4276
Viral infections in inflammatory bowel disease: Tips and tricks for correct management
Abstract
Over the past decades, the treatment of inflammatory bowel diseases (IBD) has become more targeted, anticipating the use of immune-modifying therapies at an earlier stage. This top-down approach has been correlated with favorable short and long-term outcomes, but it has also brought with it concerns regarding potential infectious complications. This large IBD population treated with immune-modifying therapies, especially if combined, has an increased risk of severe infections, including opportunistic infections that are sustained by viral, bacterial, parasitic, and fungal agents. Viral infections have emerged as a focal safety concern in patients with IBD, representing a challenge for the clinician: they are often difficult to diagnose and are associated with significant morbidity and mortality. The first step is to improve effective preventive strategies, such as applying vaccination protocols, adopt adequate prophylaxis and educate patients about potential risk factors. Since viral infections in immunosuppressed patients may present atypical signs and symptoms, the challenges for the gastroenterologist are to suspect, recognize and diagnose such complications. Appropriate treatment of common viral infections allows us to minimize their impact on disease outcomes and patients' lives. This practical review supports this standard of care to improve knowledge in this subject area.
Keywords: Crohn’s disease; Inflammatory bowel diseases; Opportunistic infections; Standard of care; Ulcerative colitis; Viral infections.
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: MA received consulting fees from Nikkiso Europe, Mundipharma, Janssen, Abbvie and Pfizer; FF received consulting fees from Amgen, Abbvie and lecture fees from Janssen and Pfizer; LP-B reports personal fees from Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, HAC-Pharma, Index Pharmaceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera, and Samsung Biosepsis; GF received consultancy fees from Ferring, MSD, AbbVie, Takeda, Janssen, Amgen, Sandoz, Samsung Bioepis, Celltrion; SD served as a speaker, consultant and advisory board member for Schering-Plough, Abbott (AbbVie) Laboratories, Merck, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos, Actelion, Alfa Wasserman, Genentech, Grunenthal, Pfizer, AstraZeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor and Johnson and Johnson. VC, AZ and SB have no conflicts of interest to declare.
Similar articles
-
Updates on vaccinating the inflammatory bowel disease patient.Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):229-239. doi: 10.1080/17474124.2019.1565993. Epub 2019 Jan 21. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30791761 Review.
-
Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease.J Infect. 2017 May;74(5):433-441. doi: 10.1016/j.jinf.2017.02.009. Epub 2017 Mar 2. J Infect. 2017. PMID: 28263759 Review.
-
The risk for opportunistic infections in inflammatory bowel disease with biologics: an update.Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108. doi: 10.1080/17474124.2018.1530983. Epub 2018 Oct 10. Expert Rev Gastroenterol Hepatol. 2018. PMID: 30277409 Review.
-
Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary.Inflamm Bowel Dis. 2016 Oct;22(10):2538-47. doi: 10.1097/MIB.0000000000000902. Inflamm Bowel Dis. 2016. PMID: 27598743 Review.
-
Vaccinating the inflammatory bowel disease patient.Expert Rev Gastroenterol Hepatol. 2015 Jan;9(1):91-102. doi: 10.1586/17474124.2014.934672. Epub 2014 Aug 27. Expert Rev Gastroenterol Hepatol. 2015. PMID: 25160668 Review.
Cited by
-
Association Between Inflammatory Bowel Disease and Viral Infections.Curr Microbiol. 2023 Apr 27;80(6):195. doi: 10.1007/s00284-023-03305-0. Curr Microbiol. 2023. PMID: 37106245 Free PMC article. Review.
-
Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.World J Hepatol. 2021 Dec 27;13(12):1828-1849. doi: 10.4254/wjh.v13.i12.1828. World J Hepatol. 2021. PMID: 35069993 Free PMC article. Review.
-
Seroprevalence of CMV infection in patients with active ulcerative colitis and underlying factors of pathogenicity.BMC Infect Dis. 2025 May 30;25(1):774. doi: 10.1186/s12879-025-11156-2. BMC Infect Dis. 2025. PMID: 40448012 Free PMC article.
-
Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review.Arch Microbiol. 2023 May 30;205(6):252. doi: 10.1007/s00203-023-03590-0. Arch Microbiol. 2023. PMID: 37249707 Free PMC article. Review.
-
Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis.Intest Res. 2023 Jan;21(1):88-99. doi: 10.5217/ir.2021.00154. Epub 2022 Mar 11. Intest Res. 2023. PMID: 35263962 Free PMC article.
References
-
- Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14:4–22. - PubMed
-
- Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110:1324–1338. - PubMed
-
- Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous